Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
Sana Biotechnology (NASDAQ: SANA) announced that it will present six abstracts, including two oral presentations, at the upcoming 64th American Society of Hematology Annual Meeting from December 10-13, 2022, in New Orleans, LA. The presentations will highlight the potential of Sana's allogeneic CAR T cell and in vivo delivery platforms for treating hematologic malignancies. Key topics include CD19, CD22, and BCMA-targeted therapeutics. The company aims to advance therapies for lymphoma, leukemia, and multiple myeloma, with a focus on innovative approaches to enhance therapeutic efficacy.
- Six abstracts accepted for presentation at ASH Annual Meeting, indicating strong research progress.
- Focus on allogeneic CAR T cell therapy for hematologic malignancies, potentially expanding treatment options.
- None.
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that six abstracts have been accepted for presentation, including two oral presentations, at the 64th American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022 in New Orleans, LA.
“The presentations at ASH will showcase the potential for both our allogeneic CAR T cell and in vivo delivery platforms to develop differentiated drugs for patients with hematologic malignancies,” said Terry Fry, Sana’s Senior Vice President and Head of T Cell Therapeutics. “We are initially developing therapeutics for patients with lymphoma, leukemia, and multiple myeloma, and we look forward to presenting data on CD19-, CD22- and BCMA-targeted therapeutic candidates at the meeting.”
Details of the oral presentations are as follows:
| Title: | Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice | |
| Abstract Number: | 485 | |
| Session Name: | 703. Cellular Immunotherapies: Basic and Translational IV | |
| Session Date: | Sunday, December 11, 2022 | |
| Session Time: | 9:30 – 11:00 a.m. CT | |
| Presentation Time: | 10:30 a.m. CT | |
| Location: | Ernest N. Morial Convention Center, 388-390 | |
| Presenter: | Sonja Schrepfer, PhD |
| Title: | Efficient and Specific Multi-Locus Editing of Allogeneic CAR T Cells for Hypoimmunity during Large Scale Manufacture Using Cas12b | |
| Abstract Number: | 663 | |
| Session Name: | 711. Cell Collection and Processing I | |
| Session Date: | Sunday, December 11, 2022 | |
| Session Time: | 4:30 – 6:00 p.m. CT | |
| Presentation Time: | 5:00 p.m. CT | |
| Location: | Ernest N. Morial Convention Center, 220-222 | |
| Presenter: | Christina Chaivorapol, PhD |
Details of the poster presentations are as follows:
| Title: | Functional T Cell Assays Are Predictive of Pre-Clinical Potency to Generate Allogeneic, Hypoimmune CD19 CAR T Cells | |
| Abstract Number: | 1974 | |
| Session Name: | 703. Cellular Immunotherapies: Basic and Translational: Poster I | |
| Session Date: | Saturday, December 10, 2022 | |
| Session Time: | 5:30 – 7:30 p.m. CT | |
| Location: | Ernest N. Morial Convention Center, Hall D | |
| Presenter: | Darin Salloum, PhD |
| Title: | A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape | |
| Abstract Number: | 1988 | |
| Session Name: | 703. Cellular Immunotherapies: Basic and Translational: Poster I | |
| Session Date: | Saturday, December 10, 2022 | |
| Session Time: | 5:30 – 7:30 p.m. CT | |
| Location: | Ernest N. Morial Convention Center, Hall D | |
| Presenter: | Adam Johnson, PhD |
| Title: | BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models | |
| Abstract Number: | 3168 | |
| Session Name: | 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II | |
| Session Date: | Sunday, December 11, 2022 | |
| Session Time: | 6:00 – 8:00 p.m. CT | |
| Location: | Ernest N. Morial Convention Center, Hall D | |
| Presenter: | Jeremy Kinder, PhD |
| Title: | CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies | |
| Abstract Number: | 3457 | |
| Session Name: | 801. Gene Therapies: Poster II | |
| Session Date: | Sunday, December 11, 2022 | |
| Session Time: | 6:00 – 8:00 p.m. CT | |
| Location: | Ernest N. Morial Convention Center, Hall D | |
| Presenter: | Jesse Green, PhD |
Full abstracts are available for online viewing via the ASH Annual Meeting website at www.hematology.org/meetings/annual-meeting. In addition, abstracts will be published online in the November supplemental issue of Blood, the journal of the American Society of Hematology.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for the Company’s participation at the 64th American Society of Hematology Annual Meeting and Exposition; and expectations for the Company’s presentations at such conference, including regarding the content of such presentations. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated November 2, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
What abstracts will Sana Biotechnology present at the ASH Annual Meeting?
What is the significance of Sana's participation in the ASH Annual Meeting?
When is the ASH Annual Meeting where Sana will present?
What types of cancers is Sana Biotechnology developing treatments for?
Where can I find full details of the abstracts presented by Sana?
